Abraham Zangen

[1] In 2003, he returned to Israel and established a laboratory at the Weizmann Institute of Science in Rehovot, attaining the rank of associate professor in 2010.[12] The MIT Technology Review reported that Zangen and his team were evaluating the potential for disrupting areas of the brain that are overactive in cases of addiction or Obsessive compulsive disorder (OCD).[13] In 2018, the FDA granted de novo clearance to deep transcranial magnetic stimulation as a non-invasive treatment for OCD, after being cleared for treatment-resistant major depressive disorder in 2013 following multicenter studies conducted by Zangen and his team.[14] In 2020, the FDA granted clearance for a different version of this technology for smoking cessation in the wake of another multicenter study.[17] In 2023, a comparative study led by Zangen validated the efficacy of two different Deep TMS coils for treatment-resistant depression.
HebrewprofessorneurosciencepsychobiologyBen-Gurion University of the NegevRamat GanpharmacologyHebrew UniversityBar Ilan UniversityU.S. National Institutes of HealthWeizmann Institute of ScienceRehovotBen Gurion University of the Negevneuroplasticityreward systembrain stimulationpsychiatric disordersdepressionaddictionattention deficitsmagnetic coiltranscranial magnetic stimulationBrainswayNational Institute on Drug AbuseMIT Technology ReviewObsessive compulsive disorderScience and technology in IsraelHealth care in IsraelList of Israeli inventions and discoveriesMakor RishonBibcodeNIH Office of Technology TransferJerusalem PostNature.com